{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T11:10:26Z","timestamp":1793445026548,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol. Sin."],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s12250-020-00295-2","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T06:04:04Z","timestamp":1601359444000},"page":"537-544","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Sensitive and High-Throughput Flow Cytometry-Based Assay for Measuring Antibody Neutralization of Human Adenovirus Type 3"],"prefix":"10.1016","volume":"36","author":[{"given":"Zhenwei","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingui","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenkuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Xian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weilue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7322-3561","authenticated-orcid":false,"given":"Rong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","published-online":{"date-parts":[[2020,9,29]]},"reference":[{"key":"295_CR1","first-page":"367","volume":"14","author":"CH Andrewes","year":"1933","unstructured":"Andrewes CH, Elford WJ (1933) Observations on Anti-Phage Sera. I: \u201cThe Percentage Law\u201d. Br J Exp Pathol 14:367\u2013376","journal-title":"Br J Exp Pathol"},{"key":"295_CR2","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1089\/104303404322886147","volume":"15","author":"M Aste-Amezaga","year":"2004","unstructured":"Aste-Amezaga M, Bett AJ, Wang F, Casimiro DR, Antonello JM, Patel DK, Dell EC, Franlin LL, Dougherty NM, Bennett PS, Perry HC, Davies ME, Shiver JW, Keller PM, Yeager MD (2004) Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: application in epidemiologic studies and in the design of adenovector vaccines. Hum Gene Ther 15:293\u2013304","journal-title":"Hum Gene Ther"},{"key":"295_CR3","first-page":"2355","volume":"5","author":"A Berk","year":"2007","unstructured":"Berk A (2007) Adenoviridae: the viruses and their replication. Fields Virol 5:2355\u20132394","journal-title":"Fields Virol"},{"key":"295_CR4","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.antiviral.2005.03.006","volume":"67","author":"N Bourne","year":"2005","unstructured":"Bourne N, Pyles RB, Yi M, Veselenak RL, Davis MM, Lemon SM (2005) Screening for hepatitis C virus antiviral activity with a cell-based secreted alkaline phosphatase reporter replicon system. Antiviral Res 67:76\u201382","journal-title":"Antiviral Res"},{"key":"295_CR5","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/BF01310968","volume":"83","author":"P Brioen","year":"1985","unstructured":"Brioen P, Boeye A (1985) Poliovirus neutralization and the percentage law. Brief report. Arch Virol 83:105\u2013111","journal-title":"Arch Virol"},{"key":"295_CR6","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.antiviral.2016.04.013","volume":"131","author":"AE Calvert","year":"2016","unstructured":"Calvert AE, Dixon KL, Piper J, Bennett SL, Thibodeaux BA, Barrett AD, Roehrig JT, Blair CD (2016) A humanized monoclonal antibody neutralizes yellow fever virus strain 17D-204 in vitro but does not protect a mouse model from disease. Antiviral Res 131:92\u201399","journal-title":"Antiviral Res"},{"key":"295_CR7","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S0166-0934(02)00122-2","volume":"105","author":"X Cheng","year":"2002","unstructured":"Cheng X, Munoz MG, Zhou H, Jin H (2002) Expression of beta-galactosidase by recombinant respiratory syncytial viruses for microneutralization assay. J Virol Methods 105:287\u2013296","journal-title":"J Virol Methods"},{"key":"295_CR8","first-page":"406","volume":"11","author":"A Cosma","year":"2004","unstructured":"Cosma A, Buhler S, Nagaraj R, Staib C, Hammarin AL, Wahren B, Goebel FD, Erfle V, Sutter G (2004) Neutralization assay using a modified vaccinia virus Ankara vector expressing the green fluorescent protein is a high-throughput method to monitor the humoral immune response against vaccinia virus. Clin Diagn Lab Immunol 11:406\u2013410","journal-title":"Clin Diagn Lab Immunol"},{"key":"295_CR9","doi-asserted-by":"publisher","first-page":"10684","DOI":"10.1128\/JVI.77.19.10684-10688.2003","volume":"77","author":"PL Earl","year":"2003","unstructured":"Earl PL, Americo JL, Moss B (2003) Development and use of a vaccinia virus neutralization assay based on flow cytometric detection of green fluorescent protein. J Virol 77:10684\u201310688","journal-title":"J Virol"},{"key":"295_CR10","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1128\/CMR.00052-07","volume":"21","author":"M Echavarria","year":"2008","unstructured":"Echavarria M (2008) Adenoviruses in immunocompromised hosts. Clin Microbiol Rev 21:704\u2013715","journal-title":"Clin Microbiol Rev"},{"key":"295_CR11","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1016\/j.vaccine.2013.05.088","volume":"31","author":"S Fuentes","year":"2013","unstructured":"Fuentes S, Crim RL, Beeler J, Teng MN, Golding H, Khurana S (2013) Development of a simple, rapid, sensitive, high-throughput luciferase reporter based microneutralization test for measurement of virus neutralizing antibodies following Respiratory Syncytial Virus vaccination and infection. Vaccine 31:3987\u20133994","journal-title":"Vaccine"},{"key":"295_CR12","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1086\/505498","volume":"43","author":"MG Ison","year":"2006","unstructured":"Ison MG (2006) Adenovirus infections in transplant recipients. Clin Infect Dis 43:331\u2013339","journal-title":"Clin Infect Dis"},{"key":"295_CR13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jviromet.2008.02.009","volume":"150","author":"MC Johnson","year":"2008","unstructured":"Johnson MC, Damon IK, Karem KL (2008) A rapid, high-throughput vaccinia virus neutralization assay for testing smallpox vaccine efficacy based on detection of green fluorescent protein. J Virol Methods 150:14\u201320","journal-title":"J Virol Methods"},{"key":"295_CR14","doi-asserted-by":"publisher","first-page":"5978","DOI":"10.1128\/JVI.02650-06","volume":"81","author":"MS Jones 2nd","year":"2007","unstructured":"Jones MS 2nd, Harrach B, Ganac RD, Gozum MM, Dela Cruz WP, Riedel B, Pan C, Delwart EL, Schnurr DP (2007) New adenovirus species found in a patient presenting with gastroenteritis. J Virol 81:5978\u20135984","journal-title":"J Virol"},{"key":"295_CR15","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.jviromet.2011.11.003","volume":"179","author":"Y Kaku","year":"2012","unstructured":"Kaku Y, Noguchi A, Marsh GA, Barr JA, Okutani A, Hotta K, Bazartseren B, Fukushi S, Broder CC, Yamada A, Inoue S, Wang LF (2012) Second generation of pseudotype-based serum neutralization assay for Nipah virus antibodies: sensitive and high-throughput analysis utilizing secreted alkaline phosphatase. J Virol Methods 179:226\u2013232","journal-title":"J Virol Methods"},{"key":"295_CR16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3390\/biomedicines6010030","volume":"6","author":"S Khanal","year":"2018","unstructured":"Khanal S, Ghimire P, Dhamoon AS (2018) The repertoire of adenovirus in human disease: the innocuous to the deadly. Biomedicines 6:30","journal-title":"Biomedicines"},{"key":"295_CR17","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.jcv.2009.09.023","volume":"46","author":"MG Lebeck","year":"2009","unstructured":"Lebeck MG, McCarthy TA, Capuano AW, Schnurr DP, Landry ML, Setterquist SF, Heil GL, Kilic S, Gray GC (2009) Emergent US adenovirus 3 strains associated with an epidemic and serious disease. J Clin Virol 46:331\u2013336","journal-title":"J Clin Virol"},{"key":"295_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jviromet.2017.04.012","volume":"247","author":"R Lin","year":"2017","unstructured":"Lin R, Heeke D, Liu H, Rao E, Marshall JD, Chio V, Cataniag F, Yu L, Zuo F, McCarthy MP (2017) Development of a robust, higher throughput green fluorescent protein (GFP)-based Epstein-Barr Virus (EBV) micro-neutralization assay. J Virol Methods 247:15\u201321","journal-title":"J Virol Methods"},{"key":"295_CR19","doi-asserted-by":"publisher","first-page":"e37532","DOI":"10.1371\/journal.pone.0037532","volume":"7","author":"Q Liu","year":"2012","unstructured":"Liu Q, Nie J, Huang W, Meng S, Yuan B, Gao D, Xu X, Wang Y (2012) Comparison of two high-throughput assays for quantification of adenovirus type 5 neutralizing antibodies in a population of donors in China. PLoS ONE 7:e37532","journal-title":"PLoS ONE"},{"key":"295_CR20","doi-asserted-by":"publisher","first-page":"e103058","DOI":"10.1371\/journal.pone.0103058","volume":"9","author":"M Liu","year":"2014","unstructured":"Liu M, Tian X, Li X, Zhou Z, Li C, Zhou R (2014) Generation of neutralizing monoclonal antibodies against a conformational epitope of human adenovirus type 7 (HAdv-7) incorporated in capsid encoded in a HAdv-3-based vector. PLoS ONE 9:e103058","journal-title":"PLoS ONE"},{"key":"295_CR21","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/nm0797-808","volume":"3","author":"C Nyberg-Hoffman","year":"1997","unstructured":"Nyberg-Hoffman C, Shabram P, Li W, Giroux D, Aguilar-Cordova E (1997) Sensitivity and reproducibility in adenoviral infectious titer determination. Nat Med 3:808\u2013811","journal-title":"Nat Med"},{"key":"295_CR22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.virol.2005.10.030","volume":"346","author":"TC Pierson","year":"2006","unstructured":"Pierson TC, Sanchez MD, Puffer BA, Ahmed AA, Geiss BJ, Valentine LE, Altamura LA, Diamond MS, Doms RW (2006) A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection. Virology 346:53\u201365","journal-title":"Virology"},{"key":"295_CR23","first-page":"493","volume":"27","author":"LJ Reed","year":"1938","unstructured":"Reed LJ, Muench H (1938) A simple method of estimating fifty percent endpoints. Am J Hyg 27:493\u2013497","journal-title":"Am J Hyg"},{"key":"295_CR24","doi-asserted-by":"publisher","first-page":"570","DOI":"10.3181\/00379727-84-20714","volume":"84","author":"WP Rowe","year":"1953","unstructured":"Rowe WP, Huebner RJ, Gilmore LK, Parrott RH, Ward TG (1953) Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc Soc Exp Biol Med 84:570\u2013573","journal-title":"Proc Soc Exp Biol Med"},{"key":"295_CR25","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1086\/338471","volume":"34","author":"MA Ryan","year":"2002","unstructured":"Ryan MA, Gray GC, Smith B, McKeehan JA, Hawksworth AW, Malasig MD (2002) Large epidemic of respiratory illness due to adenovirus types 7 and 3 in healthy young adults. Clin Infect Dis 34:577\u2013582","journal-title":"Clin Infect Dis"},{"key":"295_CR26","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.virol.2009.06.013","volume":"391","author":"J Sashihara","year":"2009","unstructured":"Sashihara J, Burbelo PD, Savoldo B, Pierson TC, Cohen JI (2009) Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay. Virology 391:249\u2013256","journal-title":"Virology"},{"key":"295_CR27","doi-asserted-by":"publisher","first-page":"5701","DOI":"10.1128\/JVI.00354-11","volume":"85","author":"D Seto","year":"2011","unstructured":"Seto D, Chodosh J, Brister JR, Jones MS, Members of the Adenovirus Research C (2011) Using the whole-genome sequence to characterize and name human adenoviruses. J Virol 85:5701\u20135702","journal-title":"J Virol"},{"key":"295_CR28","doi-asserted-by":"publisher","first-page":"5046","DOI":"10.1128\/JCM.41.11.5046-5052.2003","volume":"41","author":"MC Sprangers","year":"2003","unstructured":"Sprangers MC, Lakhai W, Koudstaal W, Verhoeven M, Koel BF, Vogels R, Goudsmit J, Havenga MJ, Kostense S (2003) Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol 41:5046\u20135052","journal-title":"J Clin Microbiol"},{"key":"295_CR29","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/1743-422X-9-253","volume":"9","author":"Y van Remmerden","year":"2012","unstructured":"van Remmerden Y, Xu F, van Eldik M, Heldens JG, Huisman W, Widjojoatmodjo MN (2012) An improved respiratory syncytial virus neutralization assay based on the detection of green fluorescent protein expression and automated plaque counting. Virol J 9:253","journal-title":"Virol J"},{"key":"295_CR30","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.2144\/97236pf01","volume":"23","author":"TT Yang","year":"1997","unstructured":"Yang TT, Sinai P, Kitts PA, Kain SR (1997) Quantification of gene expression with a secreted alkaline phosphatase reporter system. Biotechniques 23:1110\u20131114","journal-title":"Biotechniques"},{"key":"295_CR31","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.vaccine.2008.12.039","volume":"27","author":"Q Zhang","year":"2009","unstructured":"Zhang Q, Su X, Seto D, Zheng BJ, Tian X, Sheng H, Li H, Wang Y, Zhou R (2009) Construction and characterization of a replication-competent human adenovirus type 3-based vector as a live-vaccine candidate and a viral delivery vector. Vaccine 27:1145\u20131153","journal-title":"Vaccine"},{"key":"295_CR32","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1038\/emi.2017.29","volume":"6","author":"X Zheng","year":"2017","unstructured":"Zheng X, Rong X, Feng Y, Sun X, Li L, Wang Q, Wang M, Liu W, Li C, Yang Y, Zhou R, Lu J, Feng L, Chen L (2017) Seroprevalence of neutralizing antibodies against adenovirus type 14 and 55 in healthy adults in Southern China. Emerg Microbes Infect 6:e43","journal-title":"Emerg Microbes Infect"}],"container-title":["Virologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12250-020-00295-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12250-020-00295-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12250-020-00295-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T06:39:50Z","timestamp":1641278390000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12250-020-00295-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,29]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["295"],"URL":"https:\/\/doi.org\/10.1007\/s12250-020-00295-2","relation":{},"ISSN":["1674-0769","1995-820X"],"issn-type":[{"value":"1674-0769","type":"print"},{"value":"1995-820X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,29]]},"assertion":[{"value":"18 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The research was approved by the Ethics Committee at the First Affiliated Hospital of Guangzhou Medical University. All methods were performed in accordance with the relevant guidelines and regulations. Both informed and written consent was obtained from the participants who provided the samples.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal and Human Rights Statement"}}]}}